Plus Therapeutics to Present ReSPECT-LM Data at 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics, a clinical-stage company focused on developing innovative treatments for central nervous system cancers, has announced that it will present new data from its ReSPECT-LM Phase 1 trial at the 2024 San Antonio Breast Cancer Symposium. The presentation will focus on Rhenium (186Re) Obisbemeda, a novel targeted radiotherapy aimed at treating leptomeningeal metastases (LM) in breast cancer patients. This data could be a critical step toward offering a new treatment for LM, a challenging and often overlooked condition that complicates the care of patients with advanced breast cancer.

Dr. Andrew Brenner, Professor and Kolitz/Zachry Endowed Chair of Neuro-Oncology at the University of Texas Health Science Center, will present the data. Dr. Brenner, also the Co-Leader of the Experimental and Developmental Therapeutics Program, will update the audience on the Phase 1 dose escalation study of Obisbemeda. This treatment aims to offer new hope for patients suffering from leptomeningeal metastases, a severe complication that arises when cancer spreads to the membranes surrounding the brain and spinal cord. The presentation will take place at 7:30-8:30 a.m. CST on December 13th at the Henry B. Gonzalez Convention Center in San Antonio.

Leptomeningeal metastases have long been a major challenge in cancer care, with few effective treatment options. Plus Therapeutics is working to change that with its innovative approach using Rhenium (186Re) Obisbemeda. The Phase 1 trial is essential for determining the safety and effectiveness of this promising therapy. With this new data, Plus Therapeutics hopes to take a significant step forward in providing breast cancer patients with a much-needed treatment option for this serious condition.